Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 2/20 | 0.54 |
| ▸ | PRKX | P51817 | 2/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | GRK5 | P34947 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13784452 | 0.90 | ROCK1 (0.56) | KMT2AHPGDMMP13LMNATP53 | |
| SCHEMBL13784541 | 0.89 | MMP13 (0.49) | KMT2AHPGDMMP13LMNATP53 | |
| SCHEMBL13784545 | 0.89 | MMP13 (0.49) | KMT2AHPGDMMP13LMNATP53 | |
| SCHEMBL13784441 | 0.89 | MMP13 (0.48) | KMT2AHPGDMMP13LMNATP53 | |
| SCHEMBL13784543 | 0.88 | ROCK2 (0.58) | KMT2AHPGDMMP13LMNATP53 | |
| SCHEMBL1681517 | 0.88 | POLB (0.53) | KMT2AMMP13LMNAMAPTMEN1 | |
| SCHEMBL7014944 | 0.87 | RAB9A (0.58) | KMT2AHPGDLMNAMAPTCYP3A4 | |
| SCHEMBL13784438 | 0.87 | CYP2D6 (0.52) | KMT2AHPGDMMP13LMNAMAPT | |
| SCHEMBL13491702 | 0.87 | MMP13 (0.51) | KMT2AHPGDMMP13LMNATP53 | |
| SCHEMBL13491685 | 0.86 | MMP13 (0.55) | KMT2AHPGDMMP13LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | claimed |
| JP-2002537396-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | claimed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | claimed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | claimed |
| WO-2009093637-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | disclosed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | disclosed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | disclosed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | disclosed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | HAVCR2, MAVS, NTPCR | KMT2A 4352/4885HPGD 2006/4885MMP13 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.